Statistics
Last Updated
Jun 9, 2026
Table of contents
Peptides are the quiet engine behind the loudest story in medicine. The same chemical class that gave us insulin a century ago now gives us the GLP-1 drugs reshaping how the world treats diabetes and obesity, and the money, the science, and the pipeline have all exploded along with it. More than 100 peptide drugs are FDA-approved and over 1,200 more are in trials. Here is the field by the numbers, updated for 2026.
The headline numbers
Peptides in four figures.
Market size
A market on track to double.
By one widely cited estimate the peptide therapeutics market was about $46 billion in 2024 and roughly $50 billion in 2025, and on a high-single-digit growth track it reaches around $100 billion by 2034. The trajectory below plots that path. Estimates vary widely, from roughly $50 billion to over $130 billion for 2025, depending on which insulins and GLP-1s a given report counts as peptides.
Global peptide therapeutics market, plotted on a roughly 8% CAGR path. Anchored on real estimates for 2024 ($46B), 2025 ($50B), and 2034 (~$100B); years between are the projected trajectory. Source: Global Market Insights. Other forecasts run higher.
What is driving it
Two-thirds of it is metabolic.
The single biggest reason peptides are booming is the GLP-1 class. Metabolic disorders, the category that includes GLP-1 receptor agonists like semaglutide and tirzepatide, made up close to two-thirds of the peptide market in 2025. The rest spans cancer, hormonal therapies, and a long tail of other conditions.
Share of the 2025 peptide therapeutics market by application. Source: Grand View Research.
Just how dominant are these drugs? Of the ten best-selling medicines in the world in 2025, four were GLP-1 peptides. A handful of molecules now move the entire category.
Semaglutide and tirzepatide alone brought in well over $70 billion combined in 2025. Sources: company filings, industry sales rankings.
Where they come from
From insulin to lizard venom.
Peptides are not new. The first peptide drug was insulin, first given to a patient in the 1920s, and for decades the category sat quietly in the background. The modern boom traces to an unlikely source. Exenatide, one of the earliest GLP-1 drugs, was developed from a compound found in the venomous saliva of the Gila monster, a desert lizard whose digestion runs in long, slow cycles. That biology turned out to be a near-perfect template for controlling human blood sugar.
One of the drugs that launched the GLP-1 era started as a molecule in lizard venom.
The other defining fact about peptides is how they are delivered. Because the gut digests them like food, most peptides have to be injected, and injectables still account for roughly two-thirds of the market. The race now is oral delivery, the long-sought holy grail that would turn a weekly shot into a daily pill, and the first oral versions are already arriving.
Peptide drugs by route of administration. Source: ResearchAndMarkets, Mordor Intelligence. Oral formulations are the fastest-moving frontier.
The landscape
A field led by a few giants.
The market is concentrated. Novo Nordisk alone held more than 17% of it in 2024, and the top five companies, Novo, Eli Lilly, Bristol-Myers Squibb, Ferring, and Merck, controlled around 60% between them. The remaining 40% is split across a long tail of smaller players and contract manufacturers.
Approximate 2024 peptide market share. The top five together held about 60%. Source: Global Market Insights.
The pipeline
The trials dwarf the approvals.
More than 100 peptide drugs are already approved, but the development pipeline is more than ten times that size. Over 1,200 peptides are in clinical trials worldwide, with metabolic and cancer treatments leading the research, and the FDA granted 47 peptide candidates orphan status in 2024 alone.
Approved peptide drugs versus peptides in active clinical development worldwide. Sources: Roots Analysis, ResearchAndMarkets, FDA.
Where it goes next
From niche to core pipeline.
Peptides are moving from a specialty corner of pharma to the center of it. They offer high specificity and cleaner safety profiles than many small-molecule drugs, which is why companies are pouring research into them and why AI-driven discovery is now aimed squarely at finding new ones. Two near-term shifts will decide how far the category spreads: the arrival of cheaper generics, with the FDA approving the first generic GLP-1, liraglutide, in August 2025, and the move to oral formulations that remove the needle. Both would push peptides well past the patients who use them today.
Sources: Global Market Insights and Grand View Research (market size and application share); Roots Analysis, ResearchAndMarkets, and Mordor Intelligence (pipeline, route of administration, company share); the US Food and Drug Administration (approvals and orphan designations); and company financial filings. Figures are current as of 2026 and rounded. Market-size estimates vary widely by source and by how peptide drugs are defined.
Lifelong Optimization
Not your average
Checkup
Every life stage brings new biological demands. Tracking the right metrics at the right time helps you adapt, optimize performance, and extend both lifespan and healthspan.
Traditional
Manual Data Processing
Guesswork Trend Detection
Slow Campaign Setup
Multiple Tools, Multiple Logins
Reactive Decision-Making
Manual Reporting
Delayed Results
High Error Risk
Automated Data Sync
Real-Time Trend Insights
Instant AI Optimization
All-in-One Platform
Proactive AI-Driven Strategies
Auto-Generated Reports
Instant Performance Updates
AI Precision
Frequently Asked Questions
Clarity before
you commit
Answers on setup, scale, and support to remove blockers.
